

# **ALPHAGAN P- brimonidine tartrate solution/ drops**

## **Allergan, Inc.**

-----

### **HIGHLIGHTS OF PRESCRIBING INFORMATION**

These highlights do not include all the information needed to use ALPHAGAN P safely and effectively. See full prescribing information for ALPHAGAN P.

**ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%, for topical ophthalmic use**  
**Initial U.S. Approval: 1996**

### **RECENT MAJOR CHANGES**

Warnings and Precautions (5.3) 9/2025

### **INDICATIONS AND USAGE**

ALPHAGAN P is an alpha adrenergic agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. (1)

### **DOSAGE AND ADMINISTRATION**

One drop in the affected eye(s) three times daily, approximately 8 hours apart. (2)

### **DOSAGE FORMS AND STRENGTHS**

Ophthalmic solution containing 0.1% (1 mg/mL) or 0.15% (1.5 mg/mL) brimonidine tartrate. (3)

### **CONTRAINDICATIONS**

- Neonates and infants (pediatric patients younger than 2 years old). (4.1)
- Hypersensitivity Reactions. (4.2)

### **WARNINGS AND PRECAUTIONS**

Potential of vascular insufficiency. (5.1)

### **ADVERSE REACTIONS**

Most common adverse reactions occurring in approximately 5% to 20% of patients receiving brimonidine ophthalmic solution (0.1% to 0.2%) included allergic conjunctivitis, burning sensation, conjunctival folliculosis, conjunctival hyperemia, eye pruritus, hypertension, ocular allergic reaction, oral dryness, and visual disturbance. (6.1)

**To report SUSPECTED ADVERSE REACTIONS, contact AbbVie at 1-800-678-1605 or the FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

### **DRUG INTERACTIONS**

- Antihypertensives/cardiac glycosides may lower blood pressure. (7.1)
- Use with CNS depressants may result in an additive or potentiating effect. (7.2)
- Tricyclic antidepressants may potentially blunt the hypotensive effect of systemic clonidine. (7.3)
- Monoamine oxidase inhibitors may result in increased hypotension. (7.4)

### **USE IN SPECIFIC POPULATIONS**

Use with caution in pediatric patients aged 2 years and older. (8.4)

**See 17 for PATIENT COUNSELING INFORMATION.**

**Revised: 9/2025**

---

## **FULL PRESCRIBING INFORMATION: CONTENTS\***

- 1 INDICATIONS AND USAGE**
- 2 DOSAGE AND ADMINISTRATION**
- 3 DOSAGE FORMS AND STRENGTHS**
- 4 CONTRAINDICATIONS**

- 4.1 Neonates and Infants (Pediatric Patients Younger than 2 Years Old)
- 4.2 Hypersensitivity Reactions
- 5 WARNINGS AND PRECAUTIONS**
  - 5.1 Potentiation of Vascular Insufficiency
  - 5.2 Severe Cardiovascular Disease
  - 5.3 Contamination of Topical Ophthalmic Products After Use
- 6 ADVERSE REACTIONS**
  - 6.1 Clinical Trials Experience
  - 6.2 Postmarketing Experience
- 7 DRUG INTERACTIONS**
  - 7.1 Antihypertensives/Cardiac Glycosides
  - 7.2 CNS Depressants
  - 7.3 Tricyclic Antidepressants
  - 7.4 Monoamine Oxidase Inhibitors
- 8 USE IN SPECIFIC POPULATIONS**
  - 8.1 Pregnancy
  - 8.2 Lactation
  - 8.4 Pediatric Use
  - 8.5 Geriatric Use
- 10 OVERDOSAGE**
- 11 DESCRIPTION**
- 12 CLINICAL PHARMACOLOGY**
  - 12.1 Mechanism of Action
  - 12.3 Pharmacokinetics
- 13 NONCLINICAL TOXICOLOGY**
  - 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- 14 CLINICAL STUDIES**
- 16 HOW SUPPLIED/STORAGE AND HANDLING**
- 17 PATIENT COUNSELING INFORMATION**

\* Sections or subsections omitted from the full prescribing information are not listed.

---

## **FULL PRESCRIBING INFORMATION**

### **1 INDICATIONS AND USAGE**

ALPHAGAN P (brimonidine tartrate ophthalmic solution) 0.1% or 0.15% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

### **2 DOSAGE AND ADMINISTRATION**

The recommended dosage is one drop of ALPHAGAN P in the affected eye(s) three times daily, approximately 8 hours apart. ALPHAGAN P may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic product is to be used, the different products should be instilled at least 5 minutes apart.

### **3 DOSAGE FORMS AND STRENGTHS**

Ophthalmic solution containing 0.1% (1 mg/mL) or 0.15% (1.5 mg/mL) brimonidine tartrate.

### **4 CONTRAINDICATIONS**

#### **4.1 Neonates and Infants (Pediatric Patients Younger than 2 Years Old)**

ALPHAGAN P is contraindicated in neonates and infants (pediatric patients younger than 2 years old) [see *Use in Specific Populations (8.4)*].

#### **4.2 Hypersensitivity Reactions**

ALPHAGAN P is contraindicated in patients who have exhibited a hypersensitivity reaction to any component of this medication in the past.

### **5 WARNINGS AND PRECAUTIONS**

#### **5.1 Potentiation of Vascular Insufficiency**

ALPHAGAN P may potentiate syndromes associated with vascular insufficiency. ALPHAGAN P should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, or thromboangiitis obliterans.

#### **5.2 Severe Cardiovascular Disease**

Although brimonidine tartrate ophthalmic solution had minimal effect on the blood pressure of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease.

#### **5.3 Contamination of Topical Ophthalmic Products After Use**

There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface. Do not touch the tip of the dispensing container to the eye or surrounding structures. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions [see *Patient Counseling Information (17)*].

### **6 ADVERSE REACTIONS**

The following serious adverse reactions are described elsewhere in the labeling:

- Potentiation of Vascular Insufficiency [see *Warnings and Precautions (5.1)*]
- Severe Cardiovascular Disease [see *Warnings and Precautions (5.2)*]
- Contamination of Topical Ophthalmic Products after Use [see *Warnings and Precautions (5.3)*]

- Neonates and Infants (Pediatric Patients Younger than 2 Years Old) [see *Contraindications (4.1)*]

## **6.1 Clinical Trials Experience**

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adverse reactions occurring in approximately 10% to 20% of the subjects receiving brimonidine ophthalmic solution (0.1% to 0.2%) included: allergic conjunctivitis, conjunctival hyperemia, and eye pruritus. Adverse reactions occurring in approximately 5% to 9% included: burning sensation, conjunctival folliculosis, hypertension, ocular allergic reaction, oral dryness, and visual disturbance.

Adverse reactions occurring in approximately 1% to 4% of the subjects receiving brimonidine ophthalmic solution (0.1% to 0.2%) included: abnormal taste, allergic reaction, asthenia, blepharitis, blepharoconjunctivitis, blurred vision, bronchitis, cataract, conjunctival edema, conjunctival hemorrhage, conjunctivitis, cough, dizziness, dyspepsia, dyspnea, epiphora, eye discharge, eye dryness, eye irritation, eye pain, eyelid edema, eyelid erythema, fatigue, flu syndrome, follicular conjunctivitis, foreign body sensation, gastrointestinal disorder, headache, hypercholesterolemia, hypotension, infection (primarily colds and respiratory infections), insomnia, keratitis, lid disorder, pharyngitis, photophobia, rash, rhinitis, sinus infection, sinusitis, somnolence, stinging, superficial punctate keratopathy, tearing, visual field defect, vitreous detachment, vitreous disorder, vitreous floaters, and worsened visual acuity.

The following reactions were reported in less than 1% of subjects: corneal erosion, hordeolum, nasal dryness, and taste perversion.

## **6.2 Postmarketing Experience**

The following reactions have been identified during postapproval use of brimonidine tartrate ophthalmic solutions. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

- Bradycardia, depression, hypersensitivity, iritis, keratoconjunctivitis sicca, miosis, nausea, skin reactions (including erythema, eyelid pruritus, rash, and vasodilation), syncope, and tachycardia.
- Apnea, coma, hypotension, hypothermia, hypotonia, lethargy, pallor, respiratory depression, and somnolence have been reported in infants receiving brimonidine tartrate ophthalmic solutions.

## **7 DRUG INTERACTIONS**

### **7.1 Antihypertensives/Cardiac Glycosides**

Because ALPHAGAN P may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with ALPHAGAN P is advised.

### **7.2 CNS Depressants**

Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.

### **7.3 Tricyclic Antidepressants**

Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine. It is not known whether the concurrent use of these agents with ALPHAGAN P in humans can lead to resulting interference with the IOP lowering effect. Caution is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines.

### **7.4 Monoamine Oxidase Inhibitors**

Monoamine oxidase (MAO) inhibitors may theoretically interfere with the metabolism of brimonidine and potentially result in an increased systemic side-effect such as hypotension. Caution is advised in patients taking MAO inhibitors which can affect the metabolism and uptake of circulating amines.

## **8 USE IN SPECIFIC POPULATIONS**

### **8.1 Pregnancy**

#### Risk Summary

There are no adequate and well-controlled studies with ALPHAGAN P in pregnant women. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

In animal studies, brimonidine crossed the placenta and entered into the fetal circulation to a limited extent (*see Data*). Because animal reproduction studies are not always predictive of human response, ALPHAGAN P should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus.

#### Data

##### *Human Data*

Limited available data from postmarketing safety reports and published literature with topical use of brimonidine ophthalmic solution in pregnant women are insufficient to inform a drug-associated risk of pregnancy-related adverse outcomes including miscarriage, stillbirth, congenital anomaly, and events experienced by offspring while breastfeeding.

##### *Animal Data*

Embryofetal studies were conducted in pregnant rabbits administered brimonidine tartrate by daily oral gavage on gestation days 6 to 18, to target the period of organogenesis. Brimonidine caused miscarriage at 5 mg/kg/day (approximately 70- or 50-times the recommended human ophthalmic dose [RHOD] based on AUC, respectively for brimonidine tartrate 0.1% and 0.15%). The no observed adverse effect level (NOAEL) for developmental toxicity in rabbits was 1 mg/kg/day (approximately 9- and 6-fold the RHOD based on AUC, respectively for brimonidine tartrate 0.1% and 0.15%). No

treatment-related malformations were observed in rabbits. Signs of maternal sedation and fatigue were observed at all dose levels; the lowest observed adverse effect level (LOAEL) for maternal toxicity was 5 mg/kg/day, based on the dose response for these signs.

Embryofetal studies were conducted in pregnant rats administered brimonidine tartrate by daily oral gavage on gestation days 6 to 15, to target the period of organogenesis. The NOAEL for developmental toxicity was 2.5 mg/kg/day (approximately 1100- and 750-fold the RHOD based on AUC, respectively for brimonidine tartrate 0.1% and 0.15%). No treatment-related malformations were observed in rats. The LOAEL for maternal toxicity was 2.5 mg/kg/day, based on signs of sedation and fatigue. The maternal NOAEL was 1.0 mg/kg/day (250- and 180-fold the RHOD based on AUC, respectively for brimonidine tartrate 0.1% and 0.15%).

After pregnant rats received a single oral dose of <sup>14</sup>C-brimonidine tartrate, brimonidine and metabolites crossed the placenta and were detectable in fetal blood and organs.

## **8.2 Lactation**

### Risk Summary

It is not known whether brimonidine tartrate is excreted in human milk. In animal studies, brimonidine tartrate has been shown to cross the blood-brain barrier and is excreted into breast milk after oral administration to lactating rats (*see Data*). Because of the potential for serious adverse reactions, including central nervous system depression and apnea, from ALPHAGAN P in nursing infants, ALPHAGAN P is not recommended for use during lactation.

### Data

#### *Animal Data*

After a single oral dose of <sup>14</sup>C-labeled brimonidine tartrate to lactating rats, brimonidine and metabolites were detected in milk. After male and female rats received a single oral dose of <sup>14</sup>C-brimonidine tartrate, brimonidine crossed the blood-brain barrier. Radiolabel was detected in the cerebellum, cerebrum, and spinal cord.

## **8.4 Pediatric Use**

ALPHAGAN P is contraindicated in pediatric patients younger than 2 years old [*see Contraindications (4.1)*]. During postmarketing surveillance, apnea, bradycardia, coma, hypotension, hypothermia, hypotonia, lethargy, pallor, respiratory depression, and somnolence have been reported in infants receiving brimonidine.

In a well-controlled clinical study conducted in pediatric glaucoma patients aged 2 to 7 years old, the most commonly observed adverse reactions with brimonidine tartrate ophthalmic solution 0.2% dosed three times daily were somnolence (50% to 83% in pediatric patients aged 2 to 6 years old) and decreased alertness. In pediatric patients aged 7 years and older (greater than 20 kg), somnolence appears to occur less frequently (25%). Approximately 16% of pediatric patients on brimonidine tartrate ophthalmic solution 0.2% discontinued from the study due to somnolence.

## **8.5 Geriatric Use**

No overall differences in safety or effectiveness have been observed between elderly

and other adult patients.


## 10 OVERDOSAGE

Limited information exists on accidental ingestion of brimonidine in adults; the only adverse reaction reported to date has been hypotension. Symptoms of brimonidine overdose have been reported in neonates, infants, and children receiving ALPHAGAN P as part of medical treatment of congenital glaucoma or by accidental oral ingestion [see *Use in Specific Populations (8.4)*]. Treatment of an oral overdose includes supportive and symptomatic therapy; a patent airway should be maintained.

## 11 DESCRIPTION

ALPHAGAN P (brimonidine tartrate ophthalmic solution) 0.1% or 0.15%, sterile, is a relatively selective alpha-2 adrenergic receptor agonist for topical ophthalmic use.

The structural formula of brimonidine tartrate is:



5-Bromo-6-(2-imidazolidinylideneamino) quinoxaline L-tartrate; MW = 442.24

In solution, ALPHAGAN P (brimonidine tartrate ophthalmic solution) has a clear, greenish-yellow color. It has an osmolality of 250-350 mOsmol/kg and a pH of 7.4-8.0 (0.1%) or 6.9-7.4 (0.15%).

Brimonidine tartrate appears as an off-white to pale-yellow powder and is soluble in both water (0.6 mg/mL) and in the product vehicle (1.4 mg/mL) at pH 7.7.

Each mL of ALPHAGAN P contains the active ingredient brimonidine tartrate 0.1% (1 mg/mL) or 0.15% (1.5 mg/mL) with the inactive ingredients sodium carboxymethylcellulose; sodium borate; boric acid; sodium chloride; potassium chloride; calcium chloride; magnesium chloride; PURITE<sup>®</sup> 0.005% (0.05 mg/mL) as a preservative; purified water; and hydrochloric acid and/or sodium hydroxide to adjust pH.

## 12 CLINICAL PHARMACOLOGY

### 12.1 Mechanism of Action

ALPHAGAN P is a relatively selective alpha-2 adrenergic receptor agonist with a peak ocular hypotensive effect occurring at two hours post-dosing.

Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow.

## **12.3 Pharmacokinetics**

### Absorption

After ocular administration of either a 0.1% or 0.2% solution, plasma concentrations peaked within 0.5 to 2.5 hours and declined with a systemic half-life of approximately 2 hours.

### Distribution

Brimonidine was approximately 29% bound to plasma proteins in healthy subjects.

### Elimination

#### *Metabolism*

In humans, brimonidine is extensively metabolized by the liver.

#### *Excretion*

Urinary excretion is the major route of elimination of brimonidine and its metabolites. Approximately 87% of an orally-administered radioactive dose of brimonidine was eliminated within 120 hours, with 74% found in the urine.

## **13 NONCLINICAL TOXICOLOGY**

### **13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility**

#### Carcinogenesis

No compound-related carcinogenic effects were observed in either mice or rats following a 21-month and 24-month study, respectively. In these studies, dietary administration of brimonidine tartrate at doses up to 2.5 mg/kg/day in mice and 1 mg/kg/day in rats achieved approximately 150 and 120 times or 93 and 76 times the recommended human ophthalmic dose (RHOD) based on  $C_{max}$  respectively for brimonidine tartrate 0.1% or 0.15%.

#### Mutagenesis

Brimonidine tartrate was not mutagenic or clastogenic in a series of *in vitro* and *in vivo* studies including the Ames bacterial reversion test, chromosomal aberration assay in Chinese Hamster Ovary (CHO) cells, and three *in vivo* studies in CD-1 mice: a host-mediated assay, cytogenetic study, and dominant lethal assay.

#### Impairment of Fertility

A reproduction and fertility study in rats with brimonidine tartrate demonstrated no adverse effect on male or female fertility at oral doses up to 1 mg/kg (approximately 250 or 180 times the recommended human ophthalmic dose [RHOD] based on estimated AUC) respectively for brimonidine tartrate 0.1% and 0.15%.

## 14 CLINICAL STUDIES

Elevated IOP presents a major risk factor in glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss. Brimonidine tartrate has the action of lowering intraocular pressure with minimal effect on cardiovascular and pulmonary parameters.

Clinical studies were conducted to evaluate the safety, efficacy, and acceptability of ALPHAGAN P (brimonidine tartrate ophthalmic solution) 0.15% compared with ALPHAGAN administered three-times-daily in patients with open-angle glaucoma or ocular hypertension. Those results indicated that ALPHAGAN P (brimonidine tartrate ophthalmic solution) 0.15% is comparable in IOP lowering effect to ALPHAGAN (brimonidine tartrate ophthalmic solution) 0.2%, and effectively lowers IOP in patients with open-angle glaucoma or ocular hypertension by approximately 2-6 mmHg.

A clinical study was conducted to evaluate the safety, efficacy, and acceptability of ALPHAGAN P (brimonidine tartrate ophthalmic solution) 0.1% compared with ALPHAGAN administered three-times-daily in patients with open-angle glaucoma or ocular hypertension. Those results indicated that ALPHAGAN P (brimonidine tartrate ophthalmic solution) 0.1% is equivalent in IOP lowering effect to ALPHAGAN (brimonidine tartrate ophthalmic solution) 0.2%, and effectively lowers IOP in patients with open-angle glaucoma or ocular hypertension by approximately 2-6 mmHg.

## 16 HOW SUPPLIED/STORAGE AND HANDLING

ALPHAGAN P is supplied sterile, in teal opaque plastic LDPE bottles and tips, with purple high impact polystyrene (HIPS) caps as follows:

### 0.1%

5 mL in 10 mL bottle	NDC 0023-9321-05
10 mL in 10 mL bottle	NDC 0023-9321-10
15 mL in 15 mL bottle	NDC 0023-9321-15

### 0.15%

5 mL in 10 mL bottle	NDC 0023-9177-05
10 mL in 10 mL bottle	NDC 0023-9177-10
15 mL in 15 mL bottle	NDC 0023-9177-15

**Storage:** Store at 15°C to 25°C (59°F to 77°F).

## 17 PATIENT COUNSELING INFORMATION

### Handling the Container

Instruct patients that ocular solutions, if handled improperly or if the tip of the dispensing container contacts the eye or surrounding structures, can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions [see *Warnings and Precautions (5.3)*]. Always replace the cap after using. If solution

changes color or becomes cloudy, do not use. Do not use the product after the expiration date marked on the bottle.

#### When to Seek Physician Advice

Advise patients that if they have ocular surgery or develop an intercurrent ocular condition (e.g., trauma or infection), they should immediately seek their physician's advice concerning the continued use of the present multidose container.

#### Use with Other Ophthalmic Drugs

Advise patients that if more than one topical ophthalmic drug is being used, the drugs should be administered at least five minutes apart.

#### Potential for Decreased Mental Alertness

As with other similar medications, ALPHAGAN P may cause fatigue and/or drowsiness in some patients. Caution patients who engage in hazardous activities of the potential for a decrease in mental alertness.

Distributed by:

AbbVie Inc.

North Chicago, IL 60064

© 2025 AbbVie. All rights reserved.

ALPHAGAN P and its design and PURITE are trademarks of Allergan, Inc., an AbbVie company.

**abbvie**

20091160

#### **PRINCIPAL DISPLAY PANEL**

abbvie

NDC 0023-9321-10

Alphagan® P


(brimonidine tartrate  
ophthalmic solution)

0.1%

10 mL

Rx only

sterile



## PRINCIPAL DISPLAY PANEL

abbvie  
NDC 0023-9177-10  
Alphagan® P  
(brimonidine tartrate  
ophthalmic solution)  
0.15%  
10 mL  
Rx only  
sterile



## ALPHAGAN P

brimonidine tartrate solution/ drops

### Product Information

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:0023-9321
<b>Route of Administration</b>	OPHTHALMIC		

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
<b>BRIMONIDINE TARTRATE</b> (UNII: 4S9CL2DY2H) (BRIMONIDINE - UNII:E6GNX3HHTE)	BRIMONIDINE TARTRATE	1 mg in 1 mL

### Inactive Ingredients

Ingredient Name	Strength
<b>BORIC ACID</b> (UNII: R57ZHV85D4)	
<b>CALCIUM CHLORIDE</b> (UNII: M4I0D6VV5M)	
<b>MAGNESIUM CHLORIDE</b> (UNII: 02F3473H9O)	
<b>POTASSIUM CHLORIDE</b> (UNII: 660YQ98I10)	
<b>WATER</b> (UNII: 059QF0KO0R)	
<b>SODIUM BORATE</b> (UNII: 91MBZ8H3QO)	
<b>CARBOXYMETHYLCELLULOSE SODIUM, UNSPECIFIED</b> (UNII: K679OBS311)	
<b>SODIUM CHLORIDE</b> (UNII: 451W47IQ8X)	
<b>HYDROCHLORIC ACID</b> (UNII: QTT17582CB)	
<b>SODIUM HYDROXIDE</b> (UNII: 55X04QC32I)	
<b>SODIUM CHLORITE</b> (UNII: G538EBV4VF)	

## Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0023-9321-03	1 in 1 CARTON	01/25/2006	
1		3 mL in 1 BOTTLE, DROPPER; Type 0: Not a Combination Product		
2	NDC:0023-9321-05	1 in 1 CARTON	01/25/2006	
2		5 mL in 1 BOTTLE, DROPPER; Type 0: Not a Combination Product		
3	NDC:0023-9321-10	1 in 1 CARTON	01/25/2006	
3		10 mL in 1 BOTTLE, DROPPER; Type 0: Not a Combination Product		
4	NDC:0023-9321-15	1 in 1 CARTON	01/25/2006	
4		15 mL in 1 BOTTLE, DROPPER; Type 0: Not a Combination Product		

## Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA021770	01/25/2006	

## ALPHAGAN P

brimonidine tartrate solution/ drops

### Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0023-9177
Route of Administration	OPHTHALMIC		

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
BRIMONIDINE TARTRATE (UNII: 4S9CL2DY2H) (BRIMONIDINE - UNII:E6GNX3HHTE)	BRIMONIDINE TARTRATE	1.5 mg in 1 mL

### Inactive Ingredients

Ingredient Name	Strength
BORIC ACID (UNII: R57ZHV85D4)	
CALCIUM CHLORIDE (UNII: M4I0D6VV5M)	
MAGNESIUM CHLORIDE (UNII: 02F3473H90)	
POTASSIUM CHLORIDE (UNII: 660YQ98I10)	
WATER (UNII: 059QF0KO0R)	

<b>SODIUM BORATE</b> (UNII: 91MBZ8H3QO)	
<b>CARBOXYMETHYLCELLULOSE SODIUM, UNSPECIFIED</b> (UNII: K679OBS311)	
<b>SODIUM CHLORIDE</b> (UNII: 451W47IQ8X)	
<b>HYDROCHLORIC ACID</b> (UNII: QTT17582CB)	
<b>SODIUM HYDROXIDE</b> (UNII: 55X04QC32I)	
<b>SODIUM CHLORITE</b> (UNII: G538EBV4VF)	

<b>Packaging</b>				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0023-9177-05	1 in 1 CARTON	07/10/2001	
1		5 mL in 1 BOTTLE, DROPPER; Type 0: Not a Combination Product		
2	NDC:0023-9177-10	1 in 1 CARTON	07/10/2001	
2		10 mL in 1 BOTTLE, DROPPER; Type 0: Not a Combination Product		
3	NDC:0023-9177-15	1 in 1 CARTON	07/10/2001	
3		15 mL in 1 BOTTLE, DROPPER; Type 0: Not a Combination Product		

<b>Marketing Information</b>			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA021262	07/10/2001	

**Labeler** - Allergan, Inc. (144796497)